Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proscillaridin A is a cardiac glycoside of the bufadienolide class, naturally occurring in the squill plant (*Drimia maritima*). It is a potent inhibitor of the **Sodium/potassium-transporting ATPase (Na+/K+-ATPase)** pump. While historically used in Europe for the treatment of **congestive heart failure** and **cardiac arrhythmias**, recent research has focused on its repositioning as an anti-cancer agent. In **glioblastoma**, Proscillaridin A has been shown to induce GSK3β activation, which leads to the phosphorylation of the microtubule-plus-end-tracking protein EB1, resulting in altered microtubule dynamics, impaired cell migration, and selective cytotoxicity against tumor and stem-like cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proscillaridin a.